AbbVie will acquire Apogee for $135.11 per share in cash, implying a total equity value of approximately $10.9B. The deal is positioned to expand AbbVie’s differentiated immunology portfolio to reach more patients worldwide, signaling a positive growth catalyst for the combined portfolio.
AbbVie will acquire Apogee for $135.11 per share in cash, implying a total equity value of approximately $10.9B. The deal is positioned to expand AbbVie’s differentiated immunology portfolio to reach more patients worldwide, signaling a positive growth catalyst for the combined portfolio.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
strongly positive
Sentiment Score
0.55
Ticker Sentiment
